A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs PIM 447 (Primary) ; Ribociclib; Ruxolitinib
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 17 Mar 2017 Planned primary completion date changed from 26 Jul 2018 to 29 Dec 2017.
- 27 Feb 2017 Planned End Date changed from 1 Sep 2017 to 26 Jul 2018.